Literature DB >> 34138664

The impact of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in Gulf Cooperation Council countries.

Eric Andrew Finkelstein1, Jesse D Malkin2, Drishti Baid1, Ada Alqunaibet3, Khaled Mahdi4, Mohammed Bin Hamad Al-Thani5, Buthaina Abdulla Bin Belaila6, Ebrahim Al Nawakhtha7, Saleh Alqahtani8,9, Sameh El-Saharty10, Christopher H Herbst11.   

Abstract

AIMS: To estimate the current burden of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in the six countries in the Gulf Cooperation Council: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
MATERIALS AND METHODS: We used data from pre-existing datasets and the literature. We identified seven major noncommunicable diseases for which data were available: coronary heart disease, stroke, type-2 diabetes mellitus, breast cancer, colon cancer, chronic obstructive pulmonary disease, and asthma. We estimated the per unit cost (the annual cost of treating each illness for one person) of each disease, multiplied per unit cost by disease prevalence counts to generate disease-specific costs, and then summed across diseases. We calculated the cost of absenteeism and presenteeism by multiplying the gross domestic product per person in the labor force by the loss in productivity from each disease due to absenteeism and presenteeism, respectively, and the prevalence in the labor force of each disease.
RESULTS: We estimate that the direct medical costs of seven major noncommunicable diseases in Gulf Cooperation Council countries are $16.7 billion (2019 International $), equal to 0.6% of gross domestic product. We estimate that absenteeism and presenteeism due to these seven noncommunicable diseases cost 0.5 and 2.2% of gross domestic product, respectively. LIMITATIONS: Our study does not capture all noncommunicable diseases and does not capture all types of indirect costs. Our cost estimates are particularly sensitive to our assumptions regarding type-2 diabetes mellitus.
CONCLUSION: The economic burden of noncommunicable diseases in Gulf Cooperation Council countries is substantial, suggesting that successful preventive interventions have the potential to improve both population health and reduce costs. Further research is needed to capture a broader array of noncommunicable diseases and to develop more precise estimates.

Entities:  

Keywords:  Gulf Cooperation Council; I; I1; I10; I19; absenteeism; direct medical costs; noncommunicable diseases; presenteeism

Mesh:

Year:  2021        PMID: 34138664     DOI: 10.1080/13696998.2021.1945242

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  3 in total

1.  The case for investing in the prevention and control of non-communicable diseases in the six countries of the Gulf Cooperation Council: an economic evaluation.

Authors:  Khalifa Elmusharaf; Daniel Grafton; Johanna S Jung; Emily Roberts; Yahya Al-Farsi; Ameera Ali Al Nooh; Buthaina Bin Belaila; Amin ElShamy; Hamoud Al-Zuabi; Kholood Ateeq Al Mutawa; Shadha Alraisi; Najla Al Lawat; Ali Gharbal; Shaker Alomary; Alexey Kulikov; Nasim Pourghazian; Slim Slama; Dudley Tarlton; Nicholas Banatvala
Journal:  BMJ Glob Health       Date:  2022-06

2.  Direct Healthcare Costs of Moderate and Severe Work-Related Injuries: Estimates from the National Trauma Center of Qatar.

Authors:  Rafael J Consunji; Ahammed Mekkodathil; Ayman El-Menyar; Amber Mehmood; Brijesh Sathian; Adnan A Hyder; Nazia Hirani; Aisha Abeid; Hassan Al-Thani; Ruben Peralta
Journal:  Int J Environ Res Public Health       Date:  2022-01-30       Impact factor: 3.390

3.  The economic burden of overweight and obesity in Saudi Arabia.

Authors:  Jesse D Malkin; Drishti Baid; Reem F Alsukait; Taghred Alghaith; Mohammed Alluhidan; Hana Alabdulkarim; Abdulaziz Altowaijri; Ziyad S Almalki; Christopher H Herbst; Eric Andrew Finkelstein; Sameh El-Saharty; Nahar Alazemi
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.